Navigation Links
The Lancet publishes first clinical trial data of a fully bioabsorbable drug-eluting stent
Date:3/13/2008

t attack and re-treatment of a diseased lesion (ischemia-driven target lesion revascularization) in the ABSORB trial. Abbott's bioabsorbable everolimus eluting stent also demonstrated 100 percent procedural success and 94 percent device success in the ABSORB trial.

"Patients and physicians like the idea of a stent that does its job and is then absorbed away," said John A. Ormiston, M.B., Ch.B., cardiologist at Auckland City Hospital, in Auckland, New Zealand and principal investigator in the ABSORB trial. "Abbott's bioabsorbable stent has the potential to hold an artery open long enough for healing to occur, and we would expect an artery that is healed to function as it did before it became diseased."

Abbott is the only company with a fully bioabsorbable drug eluting coronary stent in clinical trials. Abbotts bioabsorbable everolimus eluting coronary stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbotts bioabsorbable stent is designed to restore blood flow in clogged coronary arteries, and to provide mechanical support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott's bioabsorbable drug eluting stent system is a great example of scientific innovation leading to a breakthrough treatment for heart disease that has the potential to improve patients' lives," said John M. Capek, Ph.D., executive vice president of medical devices, Abbott. "We look forward to continuing to evaluate the safety and effectiveness of our bioabsorbable stent platform in additional patients in the coming months."


'/>"/>

Contact: Karin Bauer
408-845-3887
Abbott Laboratories
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Two studies published in the Lancet
2. New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally
3. MediPurpose Sells 500 Millionth Safety Lancet to IMCO Member MMS Medical
4. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
5. American College of Physicians publishes The Fenway Guide to LGBT Health
6. In Honor of Hispanic Heritage Month and Spanish Speakers Worldwide International Hyperhidrosis Society Publishes Important New Patient Booklet in Spanish
7. Multiple Sclerosis Association of America Publishes Booklet about Depression in Multiple Sclerosis
8. American College of Physicians publishes "Peripheral Arterial Disease"
9. Thomson Scientific Publishes Who Is Making The Biggest Splash? - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... Cadiz Laser Spa offers the latest, most ... throughout Central Texas. The newest addition to their ... Using the revolutionary Rejuvapen micro-needling device Cadiz Laser ... a wide variety of skin issues. , The ... Spa is currently offering a special package through ...
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... a key factor to explain why antibiotic-resistant bacteria can thrive ... called plasmids appear to be the culprit. They can easily ... some carry a gene that makes bacteria drug-resistant, a new ... an antibiotic-resistant gene to a class of antibiotic called carbapenems," ...
(Date:9/17/2014)... might be able to reduce the need for invasive ... autoimmune disease lupus. , In a new study, researchers ... from nephritis kidney inflammation to interstitial fibrosis, ... A kidney biopsy is the only existing way to ... extent. , The model could also be used to ...
Breaking Medicine News(10 mins):Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2
... Corporation today announced it has requisitioned a special meeting ... return of capital to NUCRYST shareholders of approximately US$15 ... review alternatives to maximize the value of its 74.5 ... Corporations Act, NUCRYST,s Board of Directors has 20 days ...
... N.J., Dec. 1 ETHICON, Inc., a Johnson & ... of its Professional Wound Care business to One Equity Partners. ... , , Under the terms ... Wound Care product portfolio, which contains such advanced wound care ...
... Dec. 1 Democratic National Committee Chairman Howard Dean today ... 20th Anniversary: , , (Logo: ... "It,s been 20 years since the first World AIDS Day, ... be done to tackle this epidemic with both a national ...
... MassMutual Retirement Services Division has added two new ... has more than tripled in 2008 compared to last ... Dan Darby joined MassMutual on December 1 as nonprofit ... M. Palmer Whitney, national managing director, nonprofit market, for ...
... failure, study says , , MONDAY, Dec. 1 (HealthDay News) ... that cause idiosyncratic drug-induced liver injury (DILI), researchers say. ... cases of acute liver failure in the United States ... acute liver failure. , DILI is caused by a ...
... (PTSD) affects as many as one in five of all ... or terrorism. It has emotionally paralyzed survivors of 9/11 and ... accepted treatment that can lower the chance of developing the ... medical means of preventing PTSD may be just around the ...
Cached Medicine News:Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:Easing the stress of trauma 2
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... 17, 2014   MedeAnalytics today unveils ... brings complete visibility to a provider,s "mid-cycle" to ... reimbursement landscape. Powered by the industry,s leading big ... critical point between patient access and the business ... will improve revenue capture, minimize audit risk and ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Oct. 31, 2011 Covance Inc. (NYSE: ... ranked first, by a wide margin, in an independent ... trials. The majority (54 percent) of the study participants ... central laboratory, with investigators citing Covance three times more ...
... InterMune, Inc. (NASDAQ: ITMN ) today ... Shire plc, has been appointed to InterMune,s Board of ... on meeting the needs of the specialist physician. ... a leading global biopharmaceutical company with expertise in the ...
Cached Medicine Technology:Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 2Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 3InterMune Appoints Angus C. Russell to Board of Directors 2InterMune Appoints Angus C. Russell to Board of Directors 3
EPS 3501 : 3500 V, 150 mA, 100 W maximum. Constant voltage, constant current, or constant power modes. Stores and recalls three protocols. Excellent for manual DNA sequencing and IEF applications....
... power supply, with temperature probe, 100-120 and 220-240 ... 500 mA, and 400 W. The temperature probe ... and 90 degrees C during electrophoresis. Built-in infrared ... and instructions are provided. Dimensions are 27.5 x ...
... SPECIFICATIONS Form: Granular, free flowing powder EEO(-m r ): ... (3%): less than or equal to 31C Remelt ... Gel Strength (3%): greater than or equal to 500 ... equal to 1000 gm/cm 2 Moisture: less than ...
... chloride (Cl) ≤ 500 mg/kg sulfate (SO 4 ) ... Cd ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ... 10 mg/kg K ≤ 50 mg/kg Mg ≤ 50 ... Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ...
Medicine Products: